{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:46:35Z","timestamp":1781585195985,"version":"3.54.5"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019158","name":"Fundaci\u00f3n Espa\u00f1ola de Reumatolog\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019158","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.semarthrit.2023.152166","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T11:05:55Z","timestamp":1673435155000},"page":"152166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Efficacy and safety of leflunomide in the management of large vessel vasculitis: A systematic review and metaanalysis of cohort studies"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1614-8064","authenticated-orcid":false,"given":"Javier","family":"Narv\u00e1ez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00eddac","family":"LLop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Vidal-Montal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Brugarolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pol","family":"Maym\u00f3-Paituvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Palacios-Olid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan Miquel","family":"Nolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2023.152166_bib0001","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/MD.0000000000000033","article-title":"Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients","volume":"93","author":"Alba","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0002","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/rheumatology\/kev348","article-title":"Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study","volume":"55","author":"Labarca","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0003","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.semarthrit.2020.04.004","article-title":"Relapses and long-term remission in large vessel giant cell arteritis in northern Italy: characteristics and predictors in a long-term follow-up study","volume":"50","author":"Muratore","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0004","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.11388","article-title":"Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes","volume":"49","author":"Proven","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0005","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3390\/jcm11041034","article-title":"Impact of glucocorticoid cumulative doses in a real-life cohort of patients affected by giant cell arteritis","volume":"11","author":"Castan","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0006","first-page":"keab921","article-title":"Tolerance of glucocorticoids in giant cell arteritis: a study of patient-reported adverse events","author":"De Boysson","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0007","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"37","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.semarthrit.2023.152166_bib0008","article-title":"Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations","volume":"23","author":"Unizony","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0009","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.semarthrit.2021.01.006","article-title":"Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients","volume":"51","author":"Calder\u00f3n-Goercke","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0010","doi-asserted-by":"crossref","first-page":"E328","DOI":"10.1016\/S2665-9913(21)00038-2","article-title":"Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the giant cell arteritis Actemra (GiACTA) trial","volume":"3","author":"Stone","year":"2021","journal-title":"Lancet Rhumatol"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0011","article-title":"Tocilizumab for giant cell arteritis","volume":"5","author":"Antonio","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"129","key":"10.1016\/j.semarthrit.2023.152166_bib0012","doi-asserted-by":"crossref","first-page":"69","DOI":"10.55563\/clinexprheumatol\/mjm8fr","article-title":"Evidence for uncoupling of clinical and 18-FDG activity of PET\/CT scan improvement in tocilizumab-treated patients with large-vessel giant cell arteritis","volume":"39","author":"Prieto Pe\u00f1a","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0013","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1093\/rheumatology\/keab332","article-title":"Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study","volume":"60","author":"Sch\u00f6nau","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0014","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1093\/rheumatology\/keaa894","article-title":"Use of 18F-fluorodeoxyglucose positron emission tomography to monitor tocilizumab effect on vascular inflammation in giant cell arteritis","volume":"60","author":"Quinn","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0016","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/art.41774","article-title":"American College of Rheumatology\/Vasculitis foundation guideline for the management of giant cell arteritis and Takayasu arteritis","volume":"73","author":"-Maz","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0017","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001020","article-title":"Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis","volume":"5","author":"\u00c1gueda","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0018","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s00296-021-04958-5","article-title":"Corticosteroid monotherapy for the management of Takayasu arteritis-a systematic review and meta-analysis","volume":"41","author":"Misra","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0019","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.autrev.2016.12.009","article-title":"A scoping review of the use of non-biologic disease modifying anti-rheumatic drugs in the management of large vessel vasculitis","volume":"16","author":"Misra","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0020","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/modpathol.2017.10","article-title":"Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated patients","volume":"30","author":"Maleszewski","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152018","article-title":"Efficacy and safety of tofacitinib versus leflunomide with glucocorticoids treatment in Takayasu arteritis: a prospective study","volume":"55","author":"Wang","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0022","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3109\/03009742.2011.633553","article-title":"Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study","volume":"41","author":"de Souza","year":"2012","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0023","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.rbr.2015.09.007","article-title":"Leflunomide in Takayasu arteritis- a long term observational study","volume":"56","author":"de Souza","year":"2016","journal-title":"Rev Bras Reumatol Engl Ed"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0024","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.semarthrit.2019.06.009","article-title":"East China Takayasu Arteritis (ECTA) Collaboration Group Efficacy and safety of leflunomide treatment in Takayasu arteritis: case series from the East China cohort","volume":"50","author":"Cui","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0025","doi-asserted-by":"crossref","DOI":"10.1177\/2040622320922019","article-title":"Effectiveness and safety of leflunomide compared with cyclophosphamide as induction therapy in Takayasu's arteritis: an observational study","volume":"11","author":"Dai","year":"2020","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0026","article-title":"Efficacy and safety of leflunomide versus cyclophosphamide for initial-onset Takayasu arteritis: a prospective cohort study","volume":"12","author":"Ying","year":"2020","journal-title":"Ther Adv Musculoskeletal Dis"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0027","doi-asserted-by":"crossref","DOI":"10.1177\/2040622320975233","article-title":"Effectiveness and safety of methotrexate versus leflunomide in 12-month treatment for Takayasu arteritis","volume":"11","author":"Wu","year":"2020","journal-title":"Ther Adv Chronic Dis"},{"issue":"129","key":"10.1016\/j.semarthrit.2023.152166_bib0028","doi-asserted-by":"crossref","first-page":"114","DOI":"10.55563\/clinexprheumatol\/ve38dj","article-title":"Canadian Vasculitis Research Network (CanVasc) and Vasculitis Clinical Research Consortium (VCRC). Efficacy of leflunomide in the treatment of vasculitis","volume":"39","author":"Mustapha","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0029","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1097\/RHU.0000000000001703","article-title":"Long-term efficacy and safety of leflunomide in large-vessel giant cell arteritis: a single-center, 10-year experience","volume":"28","author":"Tomelleri","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0030","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10067-018-4232-x","article-title":"Does leflunomide have a role in giant cell arteritis? An open-label study","volume":"38","author":"Ho\u010devar","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0031","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1742-1241.2012.02981.x","article-title":"Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series","volume":"66","author":"Adizie","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0032","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/120638","article-title":"Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series","volume":"2013","author":"Diamantopoulos","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0033","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/03009742.2019.1575980","article-title":"Leflunomide versus methotrexate in treatment of giant cell arteritis: comparison of efficacy, safety, and drug survival","volume":"48","author":"Tengesdal","year":"2019","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0034","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/1756-185X.14319","article-title":"Efficacy of leflunomide as a steroid-sparing agent in treatment of Indian giant cell arteritis patients: a 2-year follow-up study","volume":"25","author":"Das","year":"2022","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0035","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0162-3109(00)00191-0","article-title":"Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases","volume":"47","author":"Herrmann","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0036","first-page":"230","article-title":"Leflunomide: an immune modulating drug that may have a role in controlling secondary infections with review of its mechanisms of action","volume":"14","author":"Smith","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0037","first-page":"641","article-title":"Effects of leflunomide on inflamation and fibrosis in bleomycine induced pulmonary fibrosis in wistar albino rats","volume":"5","author":"Kayhan","year":"2013","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0038","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1042\/CS20180160","article-title":"A77 1726 (leflunomide) blocks and reverses cardiac hypertrophy and fibrosis in mice","volume":"132","author":"Ma","year":"2018","journal-title":"Clin Sci"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0039","first-page":"915","article-title":"Inhibitory effect of leflunomide on hepatic fibrosis induced by CCl4 in rats","volume":"25","author":"Yao","year":"2004","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0040","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11926-020-00948-x","article-title":"Pathogenesis of giant cell arteritis and Takayasu arteritis-similarities and differences","volume":"22","author":"Watanabe","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0041","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0042","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0043","series-title":"Newcastle-Ottawa scale","year":"2022"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0044","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0045","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/rheumatology\/keab635","article-title":"French Takayasu network. Efficacy and safety of TNF-\u03b1 antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients","volume":"81","author":"Mekinian","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152166_bib0046","first-page":"S43","article-title":"Cyclophosphamide for large vessel vasculitis: assessment of response by PET\/CT","volume":"29","author":"Henes","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2023.152166_bib0047","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1007\/s00296-017-3847-6","article-title":"Cyclophosphamide could be a better choice than methotrexate as induction treatment for patients with more severe Takayasu's arteritis","volume":"37","author":"Sun","year":"2017","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0048","first-page":"1793","article-title":"Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis","volume":"30","author":"-Valsakumar","year":"2003","journal-title":"J Rheumatol"},{"issue":"124","key":"10.1016\/j.semarthrit.2023.152166_bib0049","first-page":"69","article-title":"The potential role of leflunomide in inhibiting vascular fibrosis by down-regulating type-II macrophages in Takayasu's arteritis","volume":"38","author":"Cui","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0050","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/acr.23901","article-title":"Prevalence of giant cell arteritis relapse in patients treated with glucocorticoids: a meta-analysis","volume":"72","author":"Mainbourg","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0051","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.10262","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis","volume":"46","author":"Hoffman","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0052","first-page":"495","article-title":"A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis","volume":"19","author":"Spiera","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0053","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","article-title":"Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial","volume":"134","author":"Jover","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0054","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/art.22754","article-title":"Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis","volume":"56","author":"Mahr","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0055","series-title":"Takayasu arteritis clinical trial in china (TACTIC)","year":"2022"},{"key":"10.1016\/j.semarthrit.2023.152166_bib0056","series-title":"The registry study of takayasu arteritis in east china (ECTA-cohort study)","year":"2022"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223000069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223000069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:08:39Z","timestamp":1758733719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017223000069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":56,"alternative-id":["S0049017223000069"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152166","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of leflunomide in the management of large vessel vasculitis: A systematic review and metaanalysis of cohort studies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152166","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152166"}}